NovaBridge Biosciences

We are a global biotechnology platform company focused on developing and delivering innovative treatments to global markets. We identify and develop novel therapeutics worldwide, utilizing our international infrastructure and capabilities. Our immuno-oncology pipeline includes three clinical stage programs: givastomig, uliledlimab, and ragistomig. Our core product, givastomig, is a CLDN18.2 bispecific antibody for gastric cancer and other CLDN18.2-positive gastrointestinal malignancies. Givastomig is currently in a global randomized Phase 2 study in combination with nivolumab and chemotherapy versus nivolumab and chemotherapy in first-line metastatic gastric cancer. It is also being studied in an ongoing Phase 1b study in combination with nivolumab and chemotherapy in first-line gastric cancer. An update on the dose expansion cohorts of the Phase 1b study was provided in January 2026, with further updates expected in the second half of 2026. We anticipate launching additional studies in other Claudin 18.2-positive gastrointestinal malignancies during 2026. Internal development of uliledlimab is paused as we await data from TJ Biopharma's ongoing, randomized Phase 2 study combining uliledlimab with a checkpoint inhibitor in China. Ragistomig is managed by our collaboration partner, ABL Bio, who is conducting an ongoing Phase 1 study in multiple solid tumors. Through our subsidiary Visara, we acquired rights to VIS-101, a VEGF-A ANG-2 bispecific biologic in Phase 2 development for Wet AMD and other retinal diseases, including DME. VIS-101 has completed Phase 1 trials for both Wet AMD and DME.